{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:22Z","timestamp":1788306562040,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In December 2016, three cases of serogroup B invasive meningococcal disease, including two children from the same middle school (11 to 15\u2009years old pupils), occurred in the department (administrative district) C\u00f4tes-d\u2019Armor (Brittany, France). They were infected by a rare strain (B:P1.7\u20132,4:F5\u20139:cc162), covered by the 4CMenB vaccine (Bexsero\u00ae). Four months later, two cases due to the same strain occurred in a high school in the same area (15 to 19\u2009years old students). In accordance with French recommendations, vaccination was proposed to students of both schools and to all individuals aged 11\u201319\u2009years living or studying in the hyperendemic area. We describe these vaccination campaigns, from the alert to the impact evaluation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The target population included 8884 people: 579 in the middle school, 2007 in the high school and 6298 in the community. In both schools, vaccination sessions were organized directly on site. In the community, teenagers were vaccinated by general practitioners. The vaccination campaign took place from May to October 2017. An active pharmacovigilance follow-up was set up to document adverse effects of the vaccine.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Considering the whole target population, the vaccination coverage was estimated at 43% for 1 dose and 34% for 2 doses. Higher vaccination coverage was observed in the schools (79% in the middle school and 42% in the high school for 2 doses) than in the community (27% for 2 doses). The reported adverse effects were consistent with the safety profile of the vaccine and no severe adverse effect was reported.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This vaccination campaign was the third one implemented with Bexsero\u00ae in France and constitutes a reproducible approach for future targeted vaccination campaigns. No additional cases of the same strain have occurred since the end of the campaigns in the area.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-020-09487-7","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T10:04:07Z","timestamp":1599732247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-1561","authenticated-orcid":false,"given":"Mathilde","family":"Pivette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Bernadette","family":"Hautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Beno\u00eet","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marl\u00e8ne","family":"Faisant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Antoinette","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Antona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levy-Bruhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Tillaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Scanff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Morival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Hector","family":"Aranda Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Guillaumot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Gagni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"9487_CR1","unstructured":"French national public health agency (Sant\u00e9 publique France). Infections invasives \u00e0 m\u00e9ningocoques [Invasive meningococcal infections] [Internet]. [cited 2019 Jan 4]. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque."},{"key":"9487_CR2","doi-asserted-by":"crossref","unstructured":"Parent du Chatelet I, Deghmane AE, Antona D, Hong E, Fonteneau L, Taha MK, et al. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006\u20132015. J Infect. 2017;74(6):564\u201374.","DOI":"10.1016\/j.jinf.2017.02.011"},{"key":"9487_CR3","unstructured":"French national public health agency (Sant\u00e9 publique France). Les infections invasives \u00e0 m\u00e9ningocoques en 2016 [invasive meningococcal infections in 2016] [Internet]. [cited 2019 Jan 4]. Available from: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/donnees\/les-infections-invasives-a-meningocoque-en-france-en-2016."},{"issue":"12","key":"9487_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361.","journal-title":"Lancet Infect Dis"},{"key":"9487_CR5","unstructured":"Haut Conseil de la sant\u00e9 publique. Avis relatif \u00e0 l\u2019utilisation du vaccin Bexsero\u00ae [Opinion on the use of the Bexsero vaccine]. 2013."},{"key":"9487_CR6","doi-asserted-by":"crossref","unstructured":"Rouaud P, Perrocheau A, Taha MK, Sesbou\u00e9 C, Forgues AM. Parent du Ch\u00e2telet I, et al. prolonged outbreak of B meningococcal disease in the seine-maritime department, France, January 2003 to June 2005. Eurosurveillance. 2006;11(7):178\u201381.","DOI":"10.2807\/esm.11.07.00635-en"},{"issue":"37","key":"9487_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.15.37.19665-en","volume":"15","author":"E Delisle","year":"2010","unstructured":"Delisle E, Larrieu S, Sim\u00f5es J, Laylle N, de Pommerol M, Taha MK, et al. Community outbreak of group B meningococcal disease in Southwest France - December 2008 to September 2009. Eurosurveillance. 2010;15(37):1\u20135.","journal-title":"Eurosurveillance."},{"key":"9487_CR8","doi-asserted-by":"crossref","unstructured":"Thabuis A, Tarabit K, Taha M-K, Dejour-salamanca D, Ronin V, Parent du Ch\u00e2telet I, et al. Community outbreak of serogroup B invasive meningococcal disease in Beaujolais , France, February to June 2016 : from alert to targeted vaccination. Eurosurveillance. 2018;23(28).","DOI":"10.2807\/1560-7917.ES.2018.23.28.1700590"},{"key":"9487_CR9","unstructured":"French Ministry of Social Affairs and Health. INSTRUCTION N\u00b0 DGS\/RI1\/DUS\/2014\/301 du 24 octobre 2014 relative \u00e0 la prophylaxie des infections invasives \u00e0 m\u00e9ningocoque [National recommendations and policy regarding prophylaxis of invasive meningococcal diseases]. 2014."},{"issue":"5","key":"9487_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","volume":"13","author":"U Vogel","year":"2013","unstructured":"Vogel U, Taha M-K, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416\u201325.","journal-title":"Lancet Infect Dis"},{"key":"9487_CR11","unstructured":"Haut Conseil de la sant\u00e9 publique. Avis relatif \u00e0 la poursuite de la campagne de vaccination contre le m\u00e9ningocoque B :14 :P1.7,16 dans les d\u00e9partements de la Seine-Maritime et de la Somme [Opinion on the continuation of the vaccination campaign against meningococcal B: 14:P 1.7,16]. 2013."},{"key":"9487_CR12","unstructured":"European Centre for Disease Prevention and Control (ECDC). Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU\/EEA [Internet]. Available from: https:\/\/ecdc.europa.eu\/sites\/portal\/files\/documents\/Introduction-of-4CMenB-vaccine.pdf."},{"key":"9487_CR13","doi-asserted-by":"crossref","unstructured":"Ladhani SN, Campbell H, Parikh SR, Saliba V, Borrow R, Ramsay M. The introduction of the meningococcal B (MenB) vaccine (Bexsero\u00ae) into the national infant immunisation programme - new challenges for public health. J Infect. 2015;71(6):611\u20134.","DOI":"10.1016\/j.jinf.2015.09.035"},{"key":"9487_CR14","unstructured":"Ray B, Taha M-K, Giuliani M, Pizza M, Banzhoff A, Bekkat-Berkani R. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J Infect. 2020. In Press."},{"issue":"4","key":"9487_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","volume":"382","author":"HS Marshall","year":"2020","unstructured":"Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318\u201327.","journal-title":"N Engl J Med"},{"key":"9487_CR16","doi-asserted-by":"crossref","unstructured":"Lecocq H, Parent du Ch\u00e2telet I, Taha MK, L\u00e9vy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19).","DOI":"10.1016\/j.vaccine.2016.03.020"},{"issue":"6","key":"9487_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","volume":"11","author":"F Caron","year":"2011","unstructured":"Caron F, du Ch\u00e2telet IP, Leroy J-P, Ruckly C, Blanchard M, Bohic N, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455\u201363.","journal-title":"Lancet Infect Dis"},{"key":"9487_CR18","doi-asserted-by":"crossref","unstructured":"Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384(9960):2123\u201331.","DOI":"10.1016\/S0140-6736(14)60842-4"},{"issue":"4","key":"9487_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1901229","volume":"382","author":"SN Ladhani","year":"2020","unstructured":"Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309\u201317.","journal-title":"N Engl J Med"},{"issue":"8","key":"9487_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0181817","volume":"12","author":"S Blagden","year":"2017","unstructured":"Blagden S, Seddon D, Hungerford D, Stanistreet D. Uptake of a new meningitis vaccination programme amongst first-year undergraduate students in the United Kingdom: a cross-sectional study. PLoS One. 2017;12(8):1\u201316.","journal-title":"PLoS One"},{"key":"9487_CR21","unstructured":"European medicines Agency. Summary of product characteristics Bexsero\u00ae [Internet]. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/bexsero-epar-product-information_en.pdf."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-020-09487-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-020-09487-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T23:22:51Z","timestamp":1631229771000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-020-09487-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["9487"],"URL":"https:\/\/doi.org\/10.1186\/s12889-020-09487-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,10]]},"assertion":[{"value":"15 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The French national public health agency (Sant\u00e9 publique France) is legally missioned to watch the health of French population by implementing information systems collecting health data (L. 1413\u20131 code de la sant\u00e9 Publique). This investigation was implemented in compliance with the authorization delivered to Sant\u00e9 publique France by the French data protection authority (CNIL) to process personal health data in order to prevent, alert or monitor an epidemiological crisis (authorization 341194\u2009V42).According to French law, only research involving a human being (research defined by article L. 1121\u20131 and article R. 1121\u20131 of the code de la sant\u00e9 publique) are compelled to receive the approval of ethics committee. The research involving a human being aims to improve biological or medical knowledge. This epidemiological study was based on data collected from patient charts and directly from the patient. It was not qualified as a research involving a human being research defined by article L. 1121\u20131 and article R. 1121\u20131 of the code de la sant\u00e9 publique and as a consequence did not require the approval of an ethic committee.All participants were informed in writing of the processing of their data and were able to object it. For minors under 18\u2009years old, all parents or guardians have been informed in writing of the processing of the data and were able to object it.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1382"}}